New hope for Tough-to-Treat leukemia: testing a targeted drug after chemo
NCT ID NCT04659616
Summary
This early-stage study is testing if adding a new oral drug called pemigatinib to standard chemotherapy is safe and helpful for adults newly diagnosed with a higher-risk form of acute myeloid leukemia (AML). The goal is to find the best dose of pemigatinib, which works by blocking a specific growth signal in leukemia cells. Researchers will enroll about 32 participants to see if this combination can better control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UT Southwestern/Simmons Cancer Center-Dallas
RECRUITINGDallas, Texas, 75390, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.